The Uromigos

Episode 510: ADCs in Prostate Cancer Jun 15, 2026 00:30:23 Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.

Episode 509: ASCO 2026 Review Jun 8, 2026 00:55:12 This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent studies, controversies, and future directions in GU oncology.

Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer May 31, 2026 00:39:40 Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.

Episode 507: ASCO 2026 - TALAPRO-3 May 30, 2026 00:41:45 Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients? May 30, 2026 00:19:46 This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and innovative approaches to assessment. Experts discuss the limitations of current tools, the importance of long-term follow-up, and future directions for integrating patient-centere

Episode 505 : ASCO 2026 - RAMPART May 30, 2026 00:29:31 James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.

Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer May 29, 2026 00:40:32 This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts discuss efficacy, safety, biomarkers, and future directions in bladder cancer treatment.

Episode 499: APCCC 2026 - Radioligands in Prostate Cancer May 25, 2026 00:37:18 This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, challenges, and future directions in radiopharmaceuticals.

Episode 503: ASCO 2026 Preview May 22, 2026 01:22:10 Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026

Episode 502: AUA 2026 and FDA bladder cancer meeting May 20, 2026 00:35:16 In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of drug approvals, the importance of randomized trials, and the emerging data on Deltalimagene, a non-viral gene therapy. The conversation highlights the complexities of treatment opti

Episode 501: APCCC 2026 - Biochemically-relapsed Prostate cancer May 18, 2026 00:19:39 Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.

Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..) May 11, 2026 00:35:16 Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer ahead of the ASCO 2026 plenary phase 3 data. We discuss the RAS pathway, prior unsuccessful targeting efforts and nuances on response and resistance.

Episode 498: APCCC 2026 - mCRPC May 2, 2026 00:21:30 This APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-driven therapy, and emerging treatment options.

Episode 497: Reflections on the capivasertib ODAC May 1, 2026 00:21:15 This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.

Episode 496: APCCC 2026 - mHSPC Landscape May 1, 2026 00:26:53 Rob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.

Episode 495: APCCC 2026 - Locally-advanced Prostate Cancer Apr 30, 2026 00:31:06 This episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment decisions.

Episode 494: Duration of EVP in Multiple Urothelial Cancer Settings / Paper of the Month PPARG Inverse Agonist Apr 27, 2026 00:40:05 Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.

Episode 493: The Role of Chemotherapy in mHSPC Apr 13, 2026 00:47:23 In the world of prostate cancer treatment, chemotherapy's role, especially in metastatic hormone-sensitive cases, remains a topic of much discussion and evolving understanding. In this podcast, we delve into the insights shared during a recent conversation with Dr. Deepak Kilari, a GU Medical Oncologist, exploring the nuances of chemotherapy in this context. We discuss key trials, shifting def

Episode 492: Novel Biomarkers and Targets in Germ Cell Tumors Apr 6, 2026 00:33:25 This podcast features Dr. Mike Glover from MDACC discussing recent advances in germ cell tumor research, focusing on novel biomarkers like microRNA and ctDNA, and emerging therapies targeting Claudin-6. The conversation explores how these innovations could transform diagnosis, prognosis, and treatment strategies.

Episode 490: Systemic Therapy Only in Patients wtih MIBC Mar 30, 2026 00:48:18 Laura Bukavina, Tyler Stewart and Amanda Nizam join Brian and Tom to discuss and debate a new clinical trial exploring EVP in MIBC with omission of cystectomy of clinical CR patients

Episode 489: Live Podcast From EAU Mar 16, 2026 00:48:18 Tom and Brian take the stage in London for a live podcast. With the help of several special guests from the audience, they discuss management of peri-operative therapy in bladder cancer (notably in patients who may refuse cystectomy) and also the emerging pembro plus belzutifan data in adjuvant RCC.

Episode 487: ASCO GU 2026 recap Mar 8, 2026 00:56:10 Brian, Silke and Tom discusses the latest data and insights from ASCO GU 2026 across kidney, prostate, and bladder cancer, highlighting new therapies, trial results, and future directions in urologic oncology.

Episode 486: ctDNA and utDNA Data in Peri-operative Urothelial cancer Mar 4, 2026 00:45:32 summaryThis episode explores the latest advances in circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) in bladder cancer management. Experts discuss how these biomarkers are transforming perioperative decision-making, prognosis, and personalized treatment strategies.

Episode 485: ASCO GU 2026 - LITESPARK 011: Len/Belzu vs Cabo Feb 28, 2026 00:31:27 This detailed discussion covers the latest phase three trial results in kidney cancer, focusing on LITESPARK 011: Belzutifan plus Lenvatnib versus Cabozantinib. Brian, Tom and Bob Motzer analyze efficacy, safety, and implications for treatment sequencing.

Episode 484: ASCO GU 2026 - LITESPARK 022: Adjuvant Pembro + Belzutifan in RCC Feb 28, 2026 00:36:53 This in-depth discussion explores the latest advancements in adjuvant kidney cancer treatment, focusing on the recent phase 3 trial results of belzutifan combined with Pembrolizumab (LITESPARK-022), mechanistic insights, biomarker development, and future research directions.

Episode 482: ASCO GU 2026 - SUNRISE 2 Feb 28, 2026 00:33:23 The conversation revolves around the Sunrise 2 trial, a study investigating the efficacy of TAR-200 combined with cetrilimab versus traditional chemoradiotherapy in muscle-invasive bladder cancer. The discussion covers the study's design, patient population, results, and implications for future treatment strategies, emphasizing the importance of patient selection and the potential for TAR-200 in e

Episode 483: ASCO GU 2026 - KEYNOTE B15: Neoadjuvant EVP vs Gem/Cis in Cis-eligible MIBC Feb 27, 2026 00:42:18 In this podcast , Brian, Tom and Matt Galsky discuss the B15 study data on neoadjuvant therapy for muscle invasive bladder cancer, focusing on the efficacy of EV Pembro compared to gem-cis. They explore event-free survival, overall survival, and the implications of treatment duration and individualization. The conversation also touches on the role of ctDNA in treatment decisions, alternative histo

Episode 480: ASCO GU 2026 - PEACE-3 and BRCAway Final OS Results Feb 26, 2026 00:43:08 In this episode, Evan Yu discusses the latest prostate cancer data presented at ASCO GU, focusing on the final overall survival results of the PEACE 3 trial, the implications of crossing survival curves, and the evolving role of radioligand therapy and PARP inhibitors in prostate cancer treatment.

Episode 479: Does the Timing of IO Infusion Impact Clinical Outcomes? A Critical Analysis Feb 23, 2026 00:39:47 This episode critically examines a recent Nature Medicine paper on the timing of immune therapy infusion in lung cancer, exploring the scientific plausibility, methodological concerns, and implications for future research. Tom, Brian and David McDermott debate the validity of the findings, the review process, and the need for rigorous prospective trials.

Episode 478: Prostate Cancer Working Group 4 (PCWG 4) criteria Feb 16, 2026 00:45:59 SummaryThis Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group criteria, highlighting the iterative process of developing guidelines that reflect the latest scientific evidence and clinical practices. The speakers discuss the new PCWG4 including new nomenclature, the role of imaging technologies like PSMA PET, and the importance of biomarkers and patie

Episode 476: ASCO GU 2026 Preview Feb 9, 2026 00:48:49 In this podcast , the Uromigos discuss the upcoming ASCO GU conference. They delve into the latest research findings, including phase 3 trials, combination therapies, and the significance of biomarkers in treatment. The conversation highlights the importance of belzutifan in kidney cancer and explores the evolving landscape of prostate and bladder cancer treatments. The hosts also share their pred

Episode 475: Depth of Response and Overall Survival for IO-based Regimens in mRCC: Results of an FDA Analysis Feb 2, 2026 00:30:28 In this Uromigos podcast episode, Brian and Tom engage with Elaine Chang from the FDA to discuss an analysis of depth of response as an indicator of survival in kidney cancer trials. They explore the FDA's data analysis process, the significance of tumor shrinkage, and the implications of their findings on treatment outcomes. The conversation delves into the limitations of current measurement

Episode 474: Uromigos Shorts - IO-refractory Urothelial Cancer Jan 26, 2026 00:30:42 In this episode of the Uromigos podcast, Brian Rini, Tom Powles, and Karine Tawagi discuss the complexities of immunotherapy re-challenge in bladder cancer. They explore the current landscape, including the challenges of existing data, the importance of understanding patient responses, and the potential for future research in antibody-drug conjugates (ADCs). The conversation highlights the need fo

Episode 473: Uromigos Shorts - EMBARK and BCR Prostate Cancer Jan 19, 2026 00:33:39 In this podcast, the Brian, Tm and David Einstein discuss the EMBARK study and its implications for patients with biochemically relapsed prostate cancer. They explore the criteria for high-risk patients, the role of PSMA PET imaging, and the findings related to metastasis-free survival and overall survival. The conversation also delves into treatment strategies, adverse events, and patient perspec

Episode 472: Uromigos Shorts - Variant Histology Bladder Cancer Jan 12, 2026 00:27:17 This podcast discusses the significance of variant histology in urothelial cancer, emphasizing the need for tailored treatment approaches based on histological features. Experts David Aggen, Tom Powles and Brian Rini explore various variant histologies, their implications for treatment, and the challenges in managing mixed histology tumors. The conversation highlights the importance of expert path

Episode 471: Uromigos Shorts - ADCs and BiTEs in Prostate Cancer Jan 5, 2026 00:35:11 In this podcast, Brian and Tom engage with Pedro Barata to discuss the emerging field of bispecific T cell engagers and antibody-drug conjugates (ADCs) in the treatment of prostate cancer. They explore the promising data surrounding these therapies, the challenges faced in clinical trials, and the implications of phase three studies. The discussion also touches on the comparative development of AD

Episode 470: Bladder Cancer Year in Review Dec 29, 2025 00:49:53 Tom, Brian and Silke discuss the blockbuster 2025 for urothelial cancer

Episode 469: Prostate Cancer year in Review Dec 22, 2025 00:45:14 Silke details the 2025 prostate cancer highlights

Episode 468: RCC Year in Review Dec 15, 2025 00:41:48 Brian, Tom and Silke discuss the highlights of RCC for 2025

Episode 442: The History of ARPI Development in Prostate Cancer Nov 24, 2025 00:51:12 Michael Morris from MSKCC joins us for an in-depth review of ARPI development across the spectrum of prostate caner

Episode 466: #UromigosLive 2025 - Novel Therapy in mRCC Nov 10, 2025 00:53:03 Brian and Tom tag team moderate this session which covers combination data, VEGF/PD1 bispecifics, microbiome approaches, cellular therapy and enrichment strategies.

Episode 465: #UromigosLive 2025 - Adjuvant Therapy in RCC Nov 10, 2025 00:44:49 Tom leads the panel discussion about this evolving space including the RAMPART data and the press release about pembro/belzu.

Episode 464: #UromigosLive 2025 - The Evolving Landscape of mHSPC Nov 10, 2025 00:50:04 Brian moderates a panel of Chris Sweeney, Tanya Dorff, Mike Morris, Neeraj Aggarwal and Chuck Ryan as they discus and debate the mHSPC space with many treatment options.

Episode 459: #UromigosLive 2025 - Radioligands in Prostate Cancer Nov 8, 2025 00:37:40 Brian leads a discussion of Rana McCay, Chris Sweeney and Michael Morris on the PSMAddition data and the landscape of radioligands in prostate cancer.

Episode 458: #UromigosLive 2025 - Mock ODAC Nov 8, 2025 00:45:22 Brian takes the role of the FDA and we conduct a mock ODAC on the CREST and POTOMAC data

Episode 457: #UromigosLive 2025: ADCs in Bladder Cancer Nov 7, 2025 00:56:48 Tom moderates Jun Guo, Matt Galsky, Michiel Van der Heidjen and Shilpa Gupta as they discuss this ever-expanding class of agents in bladder cancer.

Episode 456: #UromigosLive 2025: Peri-operative Therapy for Urothlial Cancer Nov 7, 2025 00:51:51 The first session from UromigosLive 2025! In this episode, Tom moderates as Jonathan Rosenberg, Matt Galsky, Kala Sridhar and Josh Meeks discuss the peri-operative space and the impact of the neoadjuvant EVP and other data.

Episode 455: ESMO 2025 Urothelial Cancer Review Oct 23, 2025 00:27:19 Tom and Brian discuss the bladder cancer highlights from ESMO 2025. Show throwing is discussed.

Episode 454: ESMO 2025 Prostate and Kidney Cancer Review Oct 23, 2025 00:46:15 Silke, Tom and Brian discuss the prostate and RCC highlights from ESMO 2025

Episode 453: ESMO 2025 - IMvigor011 Oct 20, 2025 00:37:27 Alex Wyatt joins us to discuss Tom's IMvigor011 data and the field of ctDNA

Episode 452: ESMO 2025 - DV+ toripalimab in bladder cancer Oct 19, 2025 00:42:51 Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.

Episode 451: ESMO 2025 - PSMAddition Oct 19, 2025 00:30:31 Scott Tagawa discusses his ESMO Presidential presentation on Lu-PSMA-617 in patients with mHSPC

Episode 450: ESMO 2025 - CAPITELLO Oct 19, 2025 00:21:35 Elena Castro describes the CAPITELLLO prostate cancer trial and her analysis from ESMO 2025

Episode 449: ESMO 2025 - ENZARAD Oct 19, 2025 00:28:00 Paul Nguyen and Chris Sweeney double team the ENZARAD data and put it into context with other data including STAMPEDE

Episode 448: Neoadjuvant EV/Pembro in Cis-ineligible MIBC Oct 18, 2025 00:46:21 Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. More applause!!

Episode 447: ESMO 2025 - RAMPART Oct 18, 2025 00:36:41 James Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC

Episode 446: ESMO 2025 - OPTIC and front-line RCC triplets Oct 18, 2025 00:36:20 Cristina Rodriguez joins us to discuss her data on front-line triplets, and we also discuss the prospective RNAseq-based biomarker OPTIC study

Episode 445: ESMO 2025 - Systemic Checkpoint Inhibition plus BCG in NMIBC (POTOMAC and ALBAN) Oct 17, 2025 00:36:54 Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.

Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer Oct 8, 2025 00:41:58 Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025

Episode 443: ESMO 2025 Bladder Cancer Preview Oct 2, 2025 00:32:09 Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin

Episode 441: The History of IO in Urothelial Cancer - Part 2 Sep 29, 2025 00:33:16 Jonathan Rosenberg returns to finish this two-part series on IO drug development in urothelial cancer

Episode 440: The History of IO in Urothelial Cancer - Part 1 Sep 22, 2025 00:45:39 Jonathan Rosenberg joins in this 2-part series on the history of IO-based therapy in Urothelial Cancer

Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer Sep 15, 2025 00:41:24 Gert Attard joins the show to discuss his recent Cell publication looking at tumor transcriptome-wide expression classifiers in advanced prostate cancer.

Episode 438: The History of Testis Cancer Treatment Sep 8, 2025 00:39:22 Christian Kollmannsberger joins us to walk through decades of advances in advanced testis cancer.

Episode 436: The History of IO in RCC - Part 2 Aug 25, 2025 00:36:29 We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.

Episode 435: The History of IO in RCC - Part 1 Aug 18, 2025 00:27:52 The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.

Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC Aug 4, 2025 00:48:51 Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.

Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap Jul 21, 2025 00:27:49 Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.

Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials Jul 14, 2025 00:43:59 Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.

Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers? Jul 7, 2025 00:45:46 Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.

Episode 428: ASCO 2025 Recap Jun 16, 2025 00:54:20 Brian, Tom and Silke discuss their highlights form ASCO 2025

Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC) Jun 13, 2025 00:40:27 Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.

Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC Jun 6, 2025 00:37:22 Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025

Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI Jun 4, 2025 00:19:39 Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone

Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session Jun 2, 2025 00:30:10 Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.

Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC Jun 1, 2025 00:30:49 Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.

Episode 422: ACSO 2025 - ctDNA data from NIAGARA Jun 1, 2025 00:32:40 Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.

Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer Jun 1, 2025 00:34:49 Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.

Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer Jun 1, 2025 00:24:18 Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation

Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study May 31, 2025 00:23:49 Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.

Episodes

Recommended